Vertex Pharmaceuticals Inc. Stock
Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Vertex Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 1.560% | -1.722% | -5.068% | 19.030% | -0.955% | 102.654% | 142.139% |
| Exact Sciences | -0.070% | -5.939% | -13.168% | -4.402% | -18.882% | -49.279% | -37.335% |
| Incyte Corp. | 1.150% | 0.951% | -7.557% | -27.732% | -13.976% | -31.292% | -28.859% |
| Regeneron Pharmaceuticals Inc. | 5.200% | -1.487% | -6.255% | 14.670% | 4.677% | 108.570% | 173.078% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Vertex Pharmaceuticals Inc (VRTX) has been growing consistently in the Biotechnology & Medical Research industry in recent years, as indicated by its financial statements. The company's financials, from its balance sheets to its income and cash flow statements, exhibit a strong growth in its assets, revenues, and profits.
Vertex has shown significant growth in total assets, as evidenced by a consistent increase from almost $11.75 billion in 2020 to over $18.15 billion in 2022. This growth highlights the company's strong financial position, enabling it to capitalize on investment opportunities and fuel further expansion.
The total revenue Vertex generated also increased from over $6.2 billion in 2020 to nearly $8.9 billion in 2022. The steady rise in sales is a positive sign for investors and points to the company's successful execution of its growth strategy.
Comments
News
2 Fantastic Growth Stocks to Buy Right Now
While some stocks have responded to the 2024 bull market better than others, an abundance of stocks have followed this rising tide. There's no predicting how long this next bull market will last
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known for its expertise in treating cystic fibrosis (CF). The biotech is the market leader, bringing in billions of dollars in revenue and profit
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today
Vertex Pharmaceuticals (NASDAQ: VRTX) has been through some ups and downs over the past few years. The big biotech disappointed investors when a couple of candidates outside of its specialty area of